Allarity Therapeutics, Inc. 8-K

What Happened

• Allarity Therapeutics, Inc. announced the results of its Annual Meeting of stockholders held on June 26, 2026 and disclosed that the U.S. Patent and Trademark Office granted a key U.S. patent for its stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic on June 30, 2026. At the meeting, 8,364,272 shares (54.10% of issued and outstanding shares as of the May 7, 2026 record date) were present in person or by proxy, constituting a quorum. Director Jesper Hoiland was reelected for a term expiring in 2029.

Key Details

• Quorum: 8,364,272 shares present (54.10% of outstanding shares).
• Director election: Jesper Hoiland — For 3,748,814; Withheld 187,812; Broker non‑votes 4,427,646.
• Auditor ratified: Wolf & Company, P.C. — For 8,330,862; Against 25,167; Abstentions 8,243.
• Equity plan increase approved: Amended and Restated 2021 Equity Incentive Plan increased from 1,521,990 to 2,021,990 shares — For 3,083,990; Against 823,336; Abstentions 29,300; Broker non‑votes 4,427,646.
• Other votes: Advisory approval of executive compensation (say‑on‑pay) passed; approval to issue shares under the Jan 28, 2026 Common Stock Purchase Agreement with Tumim Stone Capital LLC in excess of the Exchange Cap passed; amendment to limit officer liability failed (did not pass). Final adjournment authorization passed.

Why It Matters

• The board and governance items were resolved: a key director was reelected and the company’s auditor was ratified, providing continuity in leadership and financial oversight.
• Approval to increase the equity incentive pool and to permit share issuance under the Tumim Stone agreement may affect future dilution — investors should note the new equity reserve (2,021,990 shares) and that the company can issue shares beyond the prior Exchange Cap with shareholder approval.
• The granted USPTO patent for the stenoparib DRP companion diagnostic is a material IP development that could strengthen Allarity’s proprietary position for its diagnostic tied to stenoparib development; the company included a press release (Exhibit 99.1) announcing the grant.